Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA

Part of paid clinical trials in Orange, California.

Sponsor
Jazz Pharmaceuticals
Study ID
NCT07780968
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanidatamab — DRUG
    Administered via intravenous (IV) infusion

Study Details

The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with unresectable, locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA).

Key Dates

First listed
Aug 24, 2026
Start date
Oct 1, 2026
Status verified
Aug 2026
Primary completion
Oct 1, 2031
Completion
Oct 1, 2031

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Zanidatamab-containing Therapy
    Participants with HER2-positive locally advanced or metastatic GEA initiating a zanidatamab-containing therapy as first line (1L) treatment as part of standard-of-care treatment

Primary Outcome Measure

Average age of participants [ Time Frame: Baseline ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
UCI Health - Chao Family Comprehensive Cancer CenterOrangeCalifornia92868-
University of Texas - MD Anderson Cancer Center Gastrointestinal Cancer CenterHoustonTexas77030-

Find similar trials in Orange, CA

Nationwide
Esophageal cancer trialsGastric cancer trialsOncology trialsGI oncology trials
By condition
Esophageal cancerGastric cancer
By specialty
OncologyGI oncology
By research site
UCI Health - Chao Family Comprehensive Cancer Center· Orange, CAUniversity of Texas - MD Anderson Cancer Center Gastrointestinal Cancer Center· Houston, TX

Related Studies